Stockscreener 앱 받기
1.62
4.71%
-0.08
전일 마감가:
$1.70
열려 있는:
$1.73
하루 거래량:
30,917
Relative Volume:
0.57
시가총액:
$2.93M
수익:
$12.99M
순이익/손실:
$-27.83M
주가수익비율:
-0.00795
EPS:
-203.7366
순현금흐름:
$-26.98M
1주 성능:
-9.50%
1개월 성능:
-5.81%
6개월 성능:
-71.12%
1년 성능:
-94.00%
1일 변동 폭
$1.60
$1.73
1주일 범위
$1.60
$1.97
52주 변동 폭
$1.37
$29.70
Aptevo Therapeutics Inc Stock (APVO) Company Profile
명칭
Aptevo Therapeutics Inc
전화
206-838-0500
주소
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.62 | 2.93M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-11-05 | 개시 | Ladenburg Thalmann | Buy |
| 2017-10-05 | 재개 | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스
Aptevo advances APVO-451 toward IND-enabling studies - BioWorld News
Aptevo Therapeutics (APVO) Advances Trispecific Therapies Amid C - GuruFocus
Aptevo advances trispecific cancer therapy manufacturing - Investing.com
Aptevo Advances Trispecific APVO451 Toward Clinical Development - accessnewswire.com
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development - Stock Titan
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development - Yahoo Finance
Aptevo Therapeutics (APVO) Edges Lower to $1.82 as Shares Hold Above $1.73 SupportFactor Timing - dars.gov.et
APVO StockImmuno-Oncology Company To Watch Petersburg (cK2qyfq7CG) - Mshale
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial - Benzinga
Aptevo Therapeutics (NASDAQ: APVO) Registers 6.44M Shares for Holder Resale Following Warrant Exercises - kalkinemedia.com
Aptevo Therapeutics (APVO) Shares Fall Despite Roth Capital Opti - GuruFocus
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com Nigeria
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com South Africa
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML - Yahoo Finance
Why is Aptevo Therapeutics stock slumping today? By Investing.com - Investing.com Canada
Why is Aptevo Therapeutics stock slumping today? By Investing.com - Investing.com UK
$Aptevo Therapeutics (APVO.US)$ [Strong][Smile][Heart][Rose][Leek] - Moomoo
Aptevo Therapeutics (APVO) Reports Promising AML Trial Results A - GuruFocus
Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML - TipRanks
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com India
Aptevo reports 93% clinical benefit rate in AML trial subset - Investing.com
Aptevo Reports Strong Mipletamig Results in TP53-Mutated AML - ACCESS Newswire
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - FinancialContent
Aptevo Therapeutics Inc. SEC Filing (Sep 3, 2026) - Stock Titan
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - Yahoo Finance
Aptevo Therapeutics Inc. (APVO) Peer Comparison – Compare with Others - Value Research
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Times Herald-Record
Aptevo Therapeutics Inc. (APVO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Aptevo Therapeutics (APVO) quietly closes private funding round - Stock Titan
Aptevo (APVO) Momentum: Moves 10.07% Down to $2.41 for the Current Session; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingHagopian Line - vinanet.vn
APVO: Focusing on Three Key Areas of Development - Yahoo Finance
Aptevo Shareholders Back Board, Auditor and Incentive Plan - TipRanks
Aptevo (NASDAQ: APVO) asks holders to approve dilutive warrant deal - Stock Titan
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Weekly Recap: APVO H1 losses and Aug 13 financing via warrants, PIPE - TradingView
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Inc.: Financial Data Forecasts Estimates and Expectations | AP8 | US03835L3069 - marketscreener.com
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Inc. 6M 2026: Net loss $(13.15M), Diluted EPS $(11.19) — 10-Q Summary - TradingView
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Canada
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com UK
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - ACCESS Newswire
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - Yahoo Finance
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing - TipRanks
Aptevo raises $4.5 million through warrant and equity financing By Investing.com - Investing.com Nigeria
Aptevo Raises $4.5 Million Via Warrant Exercises and PIPE; Issues 5.6M Warrants at $4.03 - TradingView
Aptevo Therapeutics Inc (APVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):